AEON Biopharma, Inc.
AEON Biopharma, Inc. (AEON): 2 pipeline candidates · ~7 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
7.2 months
D/E -1.52 · 61% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for AEON Biopharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$19.2M
Cash
$6.2M
Quarterly Burn
$2.6M
Runway
7.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| abp-450 | Preclinical |
| ABP-450 (prabotulinumtoxinA) | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
20
Total value held
$343K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 181,058 | $178K |
| geode capital management, llc | 87,062 | $86K |
| formidable asset management, llc | 20,024 | $22K |
| xtx topco ltd | 20,424 | $20K |
| jane street group, llc | 16,376 | $16K |
| vanguard fiduciary trust co | 14,702 | $14K |
| blackrock, inc. | 2,834 | $3K |
| steward partners investment advisory, llc | 1,100 | $1K |
| citigroup inc | 742 | $731 |
| wolff wiese magana llc | 567 | $559 |
Showing top 10 of 20 institutional holders of AEON Biopharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AEON Biopharma, Inc.'s pipeline?
AEON Biopharma, Inc. (AEON) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AEON Biopharma, Inc.'s lead drug candidate?
AEON Biopharma, Inc.'s most advanced tracked candidate is abp-450 (Preclinical) for Therapeutic indications for which Botox® is approved (including chronic migraine, cervical dystonia, blepharospasm, strabismus, overactive bladder, adult and pediatric detrusor overactivity, adult and pediatric upper and lower spasticity and axillary hyperhidrosis).
What is AEON Biopharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AEON Biopharma, Inc. has approximately 7.2 months of cash runway.
What is AEON Biopharma, Inc.'s market capitalization?
AEON Biopharma, Inc.'s market capitalization is approximately $19.2M.
Who is the CEO of AEON Biopharma, Inc.?
Mr. Robert Bancroft is the chief executive officer of AEON Biopharma, Inc. (AEON).
Get the full picture on AEON Biopharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.